TABLE 3: Kaplan-Meier analysis
for disease-free survival (DFS) and overall survival (OS).
The Kaplan-Meier analysis
for adjuvant chemotherapy versus no adjuvant chemotherapy failed to show improvement in DSS (log-rank p = 0.16) and RFS (log-rank p = 0.34) but did show a significant improvement in OS (log-rank p = 0.0039) (Fig.
For cTnT, the Kaplan-Meier analysis
was performed using the second specimen cTnT concentrations in 3 groups, with cutoffs based on the LoD (0.01 ug/L) and the 10% CV concentration determined within the Hamilton Regional Laboratory Medicine program using the Bio-Rad Liquicheck [TM] Cardiac Markers Control LT-level low QC material (0.04 ug/L - total imprecision).
showed no significant difference in overall survival at 24 months (60% vs.
demonstrated a significant difference between NMP22-positive and NMP22-negative groups in terms of recurrence-free survival, p = 0.038 (Fig.
Variables were banded into thirds, and Kaplan-Meier analysis
with log-rank test was used for univariate survival analysis.
The independent t-test, Chi-square test, Mann-Whitney U-test, and Kaplan-Meier analysis
Unfortunately, neither PSAHL nor PSA response determined 42 days postdocetaxel correlated to survival in Kaplan-Meier analysis
or Cox-regression analysis.
Statistical analyses included the [chi square] test, Kaplan-Meier analysis
, logistic regression, the Pearson correlation coefficient, and the Wilcoxon test.
showed that patients with AAC or CVC had a significant greater number of all-cause and cardiovascular deaths than those without.
demonstrated that HPR based on the LTA and mTEG was associated with almost 3-fold increased risk of MACE at 1-year follow-up.
Participants with LV hypertrophy had an increased risk for CV events in Kaplan-Meier analysis
, particularly after five years.